异种移植
医学
食品药品监督管理局
经济短缺
临床试验
非人灵长类
药品审批
器官捐献
移植
重症监护医学
药理学
药品
外科
病理
语言学
哲学
进化生物学
政府(语言学)
生物
标识
DOI:10.1016/j.ajt.2024.03.001
摘要
The US Food and Drug Administration (FDA) appears poised to approve a human xenotransplantation clinical trial, perhaps as early as 2025. Although the approval will likely be based on work in nonhuman primates, investigators performing research with the new decedent model hope that their efforts will help to derisk human xenotransplantation.1 The 2 approaches (nonhuman primates and decedent) at times, however, appear to be in conflict as transplant teams from across the country rush to be the first to save what they agree to be the thousands of lives lost every day due to organ shortages.
科研通智能强力驱动
Strongly Powered by AbleSci AI